Privately-held inflammation specialist Evommune has entered into an exclusive license agreement with the Eli Lilly (NYSE: LLY) subsidiary Dermira to develop and commercialize three development programs.
These investigational compounds include IRAK4/TrkA, a small molecule that broadly inhibits innate inflammation, RORγt, a small molecule addressing Th17 mediated inflammation and MRGPRX2, a small molecule to treat chronic pruritus.
"Our leadership team was pivotal in the original development of these compounds at Dermira"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze